Medical devices maker Xenocor has received $10m in Series A financing to support the launch and rapid adoption of its 5mm articulating and single-use laparoscope system, Saberscope.
Led by GenHenn Venture Fund I, the funding round also involved Barvest Ventures, Baranco Investments and Patel Family Investments as participants.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Saberscope system is designed for use in endoscopy and endoscopic surgery within the thoracic and peritoneal cavities including the female reproductive organs.
The system is already approved by the US Food and Drug Administration (FDA) for use in laparoscopic and thoracoscopic surgery.
Xenocor CEO Charles DeCoster IV said: “Xenocor is laser-focused on facilitating the evolution of the 35-year-old laparoscopic visualisation model to something that clearly better serves caregivers and patients during minimally invasive surgery.
“Our FDA-cleared Saberscope improves visualisation, dramatically diminishes workflow complexity, increases safety and reduces waste.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPlanned to be launched this year, the Saberscope helps to phase out fog and improves visualisation for the surgeon through smoke and steam.
With the ability to articulate 90° in any direction, the device provides surgeons with a full view of the anatomy at any point during the procedure.
The non-conducting system does not get too hot to initiate combustion. It can also fit in a Xenocor recycle bin and can be replaced with a new one.
Michael Hennessy Jr from GenHenn Capital will join Xenocor’s board of directors to support the growth of the company. In August last year, Xenocor received patent protection for the Saberscope system from the United States Patent and Trademark Office.
